Scarica l'app Stockscreener
3.42
5.88%
0.19
Dopo l'orario di chiusura:
3.44
0.02
+0.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune (NASDAQ:ALT) Trading Up 9.2%Should You Buy? - MarketBeat
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
Altimmune Inc (ALT) News, Articles, Events & Latest Updates - Stocktwits
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? - Yahoo Finance
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus - Yahoo Finance
HC Wainwright Estimates Altimmune's Q3 Earnings (NASDAQ:ALT) - MarketBeat
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10% - Stocktwits
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
Altimmune (ALT) Rises 2.08% to $2.94 as Shares Hold Above Key SupportActive ETF Flow - Vinanet
Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Altimmune Stock Price Forecast. Should You Buy ALT? - StockInvest.us
9 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Altimmune (ALT) Q2 2026 Earnings Call: PERFORMA Starts, Cash Reaches $519M - TradingKey
ALT|Altimmune Inc|Price:3.120|Chg%:+0.150 - TradingKey
Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares - GuruFocus
Altimmune CEO Jerome Benedict Durso Buys 15,000 Shares at $2.95 Each - Kalkine Media
Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each - Stock Titan
Altimmune: Pemvidutide Performs, But A Long Wait Ahead (NASDAQ:ALT) - Seeking Alpha
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - The Globe and Mail
Barclays Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript - GuruFocus
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Altimmune (NASDAQ:ALT): What Does the Latest Update Mean for Trial Execution? - kalkinemedia.com
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT - MarketBeat
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... - Yahoo Finance Australia
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancin - GuruFocus
Altimmune Reports Q2 2026 Financial Results and SEC Filing Highlighting Increased Assets and Equity Raise - kalkinemedia.com
Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary - TradingView
Altimmune (ALT) grows cash reserves above $518M while advancing Phase 3 MASH trial - Stock Titan
Altimmune (ALT) Advances Clinical Trials Amidst High Price-to-Sa - GuruFocus
Altimmune Releases Q2 2026 Financial Results - AlphaStreet
William Blair Maintains Altimmune(ALT.US) With Hold Rating - Moomoo
Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Altimmune Q2 EPS $(0.12) beats $(0.15) estimate - scanx.trade
Earnings call transcript: Altimmune tops Q2 2026 EPS view as shares rise - Investing.com Australia
Altimmune Q2 Earnings Call Highlights - MarketBeat
Altimmune Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Altimmune (ALT) Q2 Earnings Beat Expectations but Remain Unprofi - GuruFocus
Q2 2026 Altimmune Inc Earnings Call Transcript - GuruFocus
Form 8K Altimmune Inc For: 12 August By Investing.com - Investing.com South Africa
Altimmune posts smaller-than-expected Q2 net loss per share - TradingView
Altimmune posts $22.8M Q2 net loss, $519M cash; advances pemvidutide Phase 3 and Phase 2 programs - TradingView
Altimmune Announces Second Quarter 2026 Financial Results and Business Update - The Manila Times
Altimmune Reports $22.8 Million Q2 Loss and Advances Pemvidutide Trials - Quiver Quantitative
Altimmune (NASDAQ:ALT): What Could Today’s clinical evidence and program focus Update Reveal? - Kalkine Media
Altimmune (ALT) Q2 Earnings Preview: Unpacking Valuation and Gur - GuruFocus
Altimmune (ALT) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Attention to Clinical PipelineForward Guidance Trends - Vinanet
Altimmune Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Weekly Recap: Altimmune (ALT) PERFORMA Phase 3 launch and Aug 12 results - TradingView
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):